ATE429926T1 - Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern - Google Patents

Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern

Info

Publication number
ATE429926T1
ATE429926T1 AT01912573T AT01912573T ATE429926T1 AT E429926 T1 ATE429926 T1 AT E429926T1 AT 01912573 T AT01912573 T AT 01912573T AT 01912573 T AT01912573 T AT 01912573T AT E429926 T1 ATE429926 T1 AT E429926T1
Authority
AT
Austria
Prior art keywords
plasmin
provisional matrix
formation
matrix
remodeling
Prior art date
Application number
AT01912573T
Other languages
English (en)
Inventor
Martijn Gebbink
Emile Voest
Original Assignee
Crossbeta Biosciences Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crossbeta Biosciences Bv filed Critical Crossbeta Biosciences Bv
Application granted granted Critical
Publication of ATE429926T1 publication Critical patent/ATE429926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT01912573T 2000-02-25 2001-02-26 Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern ATE429926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200664A EP1130031A1 (de) 2000-02-25 2000-02-25 Verfahren zur Hemmung der Angiogenese unter Verwendung von Molekülen die die Plasminbildung steigern oder die Plasminaktivität verlängern
PCT/NL2001/000155 WO2001062799A2 (en) 2000-02-25 2001-02-26 Method for inhibiting angiogenesis using molecules that enhance plasmin activity

Publications (1)

Publication Number Publication Date
ATE429926T1 true ATE429926T1 (de) 2009-05-15

Family

ID=8171096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01912573T ATE429926T1 (de) 2000-02-25 2001-02-26 Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern

Country Status (7)

Country Link
US (2) US20030050245A1 (de)
EP (2) EP1130031A1 (de)
AT (1) ATE429926T1 (de)
AU (1) AU4126201A (de)
CA (1) CA2400823A1 (de)
DE (1) DE60138524D1 (de)
WO (1) WO2001062799A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
EP1820806A1 (de) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinitätsbereiche
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
AU2003252039A1 (en) 2002-07-23 2004-02-09 Vegenics Limited Methods and compositions for activating or inhibiting vegf-d and vegf-c
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
AU2006267176A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
WO2007008073A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
US20230173039A1 (en) * 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
EP4122489A4 (de) * 2020-03-24 2023-04-12 Talengen International Limited Verfahren und arzneimittel zur förderung des abbaus von missgefaltetem protein und aggregat daraus
EP4140498A4 (de) 2020-05-11 2023-11-01 Talengen International Limited Verfahren und arzneimittel zur behandlung von spinaler muskelatrophie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (de) * 1988-06-11 1989-12-21 Behringwerke Ag Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
SE9101853D0 (sv) * 1991-06-17 1991-06-17 Jonas Wadstroem Improved tissue ashesive
US5491129A (en) * 1992-07-30 1996-02-13 Yeda Research And Development Co. Ltd. Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
DE4242736A1 (de) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
CA2188647A1 (en) * 1994-05-02 1995-11-09 Stewart Anthony Cederholm-Williams Recombinant fibrin chains, fibrin and fibrin-homologs
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives

Also Published As

Publication number Publication date
EP1257582B1 (de) 2009-04-29
AU4126201A (en) 2001-09-03
DE60138524D1 (de) 2009-06-10
WO2001062799A3 (en) 2002-04-04
WO2001062799A2 (en) 2001-08-30
US20030050245A1 (en) 2003-03-13
CA2400823A1 (en) 2001-08-30
EP1130031A1 (de) 2001-09-05
US20060270599A1 (en) 2006-11-30
EP1257582A2 (de) 2002-11-20

Similar Documents

Publication Publication Date Title
ATE429926T1 (de) Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern
Delaissé et al. Proteinases in bone resorption: obvious and less obvious roles
Anand et al. A model for the formation and lysis of blood clots
Dahlbäck The protein C anticoagulant system: inherited defects as basis for venous thrombosis
FR15C0003I2 (fr) Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
DK36991D0 (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
Thelwell et al. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1
Gailani et al. Structural and functional features of factor XI
DE60035274D1 (de) Vorrichtung zum spalten von mauerwerksblöcken mit vorsprüngen neben spaltmessern
ATE315233T1 (de) Verfahren zur bestimmung des antikoagulatorischen potentials einer probe und verfahren zur bestimmung der glykosilierung von thrombomodulin
Masuda et al. cDNA cloning and characterization of vascular apoptosis-inducing protein 1
DE3780485D1 (de) Verfahren zur photometrischen bestimmung der protein c- und/oder protein s-aktivitaet.
ATE310092T1 (de) Verfahren zur herstellung von rekombinantem trypsin
Babarina et al. Role of the subchondral vascular system in endochondral ossification: endothelial cell-derived proteinases derepress late cartilage differentiation in vitro
ATE459091T1 (de) Methode zum entfernen einer mikroskopischen probe von einem substrat
DE60227335D1 (de) Kontinuierliches Verfahren zur Modifizierung von Stärke und Stärkederivate mittels Verzweigungsenzyme
DE59309646D1 (de) Verfahren zur Spaltung von Proenzymen
Leonardi et al. Structural and biochemical characterisation of VaF1, a P-IIIa fibrinogenolytic metalloproteinase from Vipera ammodytes ammodytes venom
DE60230147D1 (de) Verfahren zur überwachung und modulierung von proteinfaltung
DE60239450D1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
DE60038281D1 (de) Verfahren zur herstellung von optisch aktiven pyridinethanol-derivaten
Dar’ya et al. Meizothrombin preparation and its role in fibrin formation and platelet aggregation
DE60039034D1 (de) Verfahren und vorrichtung zum steuern von schleifmittelstromesbearbeitung
Zhou et al. A novel disintegrin, jerdonatin, inhibits platelet aggregation and sperm–egg binding

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties